AbbVie secures another Humira settlement
12-10-2018
AbbVie and Mylan agree Humira licensing deal
18-07-2018
AbbVie and Amgen settle Humira clash
29-09-2017
AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Sandoz, patent infringement, generics, BPCIA, injunction, biosimilars
